Previous 10 | Next 10 |
SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 20, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it has received a notification letter from The Nasdaq Stock Market...
SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 17, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that Matt Coffey, President & CEO of Oncolytics Biotech, will pr...
SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 5, 2019 / Oncolytics Biotech ® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that Kirk Look, Chief Financial Officer of Oncolytics Biotech, will ...
SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 4, 2019 / Oncolytics Biotech ® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced it will host a conference call and live webcast for Analysts and In...
SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / August 16, 2019 / Oncolytics Biotech ® Inc. (NASDAQ:ONCY)(TSX:ONC) (the “Company”), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the closing of its previously anno...
This is a correction to our previous announcement to highlight currency of the pricing SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / August 14, 2019 / Oncolytics Biotech ® Inc. (NASDAQ:ONCY) (TSX:ONC) (the “Company”), currently developing pelareorep, an...
Thinly traded nano cap Oncolytics Biotech (NASDAQ: ONCY ) slumps 29% premarket on increased volume in response to its public offering of ~4.6M common shares and accompanying five-year warrants to purchase up to the same number of shares at a combined price of $0.81. More news...
SAN DIEGO, CA & CALGARY, AB / ACCESSWIRE / August 14, 2019 / Oncolytics Biotech ® Inc. (NASDAQ:ONCY) (TSX:ONC) (the “Company”), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the pricing of its previously annou...
Oncolytics Biotech (NASDAQ: ONCY ): Q2 GAAP EPS of -$0.26 misses by $0.07 . More news on: Oncolytics Biotech Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
SAN DIEGO, CA and CALGARY, AB, August 13, 2019 / Oncolytics Biotech ® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it intends to offer to sell common shares and warrants to purchase comm...
News, Short Squeeze, Breakout and More Instantly...
Oncolytics Biotech Inc. Company Name:
ONCY Stock Symbol:
NASDAQ Market:
Oncolytics Biotech Inc. Website:
Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program Canada NewsWire Clear path forward on key elements of the planned potential registration-enabling trial in HR+/HER2- metastatic breast cancer On track to report ove...
Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence Canada NewsWire Wayne Pisano , Chair of Oncolytics' Board of Directors, to serve as interim CEO Overall Survival data from BRACELET-1 breast ca...
2024-06-20 17:01:11 ET USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 20,2024 – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number o...